CTIM-38. NEUROTOXICITY AND MANAGEMENT OF PRIMARY AND SECONDARY CNS LYMPHOMA AFTER ADOPTIVE IMMUNOTHERAPY WITH CD19-DIRECTED CAR T-CELLS

Abstract BACKGROUND Chimeric antigen receptor (CAR) T-cells targeting CD19 have been established as a leading engineered T-cell therapy for systemic B-cell lymphomas; however, efficacy data for patients with CNS involvement are limited. Also, there are concerns about increased neurotoxicities (denot...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Neuro-oncology (Charlottesville, Va.) Va.), 2023-11, Vol.25 (Supplement_5), p.v71-v71
Hauptverfasser:	Karschnia, Philipp, Arrillaga-Romany, Isabel, Eichler, April, Forst, Deborah, Gerstner, Elizabeth, Jordan, Justin T, Ly, Ina, Plotkin, Scott R, Wang, Nancy, Martinez-Lage, Maria, Winter, Sebastian F, Tonn, Joerg-Christian, Rejeski, Kai, von Baumgarten, Louisa, Cahill, Daniel, Nahed, Brian V, Shankar, Ganesh M, Abramson, Jeremy S, Barnes, Jeffrey A, El-Jawahri, Areej, Hochberg, Ephraim P, Johnson, P Connor, Soumerai, Jacob D, Takvorian, Ronald W, Chen, Yi-Bin, Frigault, Matthew J, Dietrich, Jorg
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical Trials: Immunologic
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!